Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05120193 · ClinicalTrials.gov registry record · NA
Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System
A NA study, sponsored by Medtronic Cardiac Ablation Solutions.
- Completed
- Registry status
- NA
- Development phase
- 477
- Enrollment target
NCT05120193 is a NA study that has completed, run by Medtronic Cardiac Ablation Solutions. The registered enrollment target is 477 participants.
The verdict
NCT05120193, a NA study, has completed, sponsored by Medtronic Cardiac Ablation Solutions.
- COMPLETED
- Registry status
- NA
- Development phase
- 477 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, randomized clinical evaluation of the Sphere-9 Mapping and Ablation Catheter with the Affera Mapping and Ablation System. Subjects will be randomly assigned 1:1 to receive treatment with either the Sphere-9 Mapping and Ablation Catheter and the Affera Mapping and Ablation System (investigational device) or the THERMOCOOL SMARTTOUCH® SF radiofrequency ablation catheter (control device).
Interventions
- DEVICE Mapping and Ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2024-01-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05120193
The ClinicalTrials.gov registry entry for NCT05120193 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 477 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Ablation Solutions, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mapping and Ablation is the first listed.
NCT05120193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05120193 about?
NCT05120193 is a clinical study titled "Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System". This is a prospective, multicenter, randomized clinical evaluation of the Sphere-9 Mapping and Ablation Catheter with the Affera Mapping and Ablation System. Subjects will be randomly assigned 1:1 to receive treatment with either the Sphere-9 Mapping and Ablation Catheter and the Affera Mapping and ...
What is the current status of trial NCT05120193?
This trial is currently completed. It is a NA study. The enrollment target is 477 participants. The study started on 2021-12-14. Estimated completion is 2024-01-10.
What interventions are being tested in trial NCT05120193?
The interventions under investigation include: Mapping and Ablation (DEVICE).
Who is sponsoring clinical trial NCT05120193?
This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.